Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies
Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.
Scrip - April 29, 2025

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
Scrip - April 29, 2025

Another CRL Prompts Questions About Regeneron’s Regulatory Operations
CEO Len Schleifer explained on the company’s Q1 earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.
Scrip - April 29, 2025

Soriot Cautions Europe Amid More US Expansion
The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."
Scrip - April 29, 2025

AstraZeneca’s Truqap Trips Up In Prostate Cancer Study
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.
Scrip - April 29, 2025

Stock Watch: Sanofi, Merck Open Windows Into Geopolitical Risks
First-quarter results season featured tariff talk but without any full-year quantitation. As tariffs and foreign exchange movements bump up against capped drug prices, profitability could suffer.
Scrip - April 29, 2025

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
Scrip - April 29, 2025

EU Approves Tremfya In Third Indication, Ulcerative Colitis
J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.
Scrip - April 29, 2025

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO
Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs
Scrip - April 29, 2025

In Brief: Amgen Invests $900m In US Manufacturing
Amgen announces major expansion of existing US site amid ongoing threat of pharma import tariffs.
Scrip - April 29, 2025

No FDA Reorg Planned, Makary Says
FDA Commissioner Marty Makary stated in a new interview that there will be no significant reorganization of the agency, despite earlier reports. Using his “guiding principles” of common sense and gold-standard science, he plans to focus on reforms including improved pathways for medical AI and food safety as well as addressing employee morale.
Medtech Insight - April 29, 2025

Roche Diagnostics Hit By China Reforms As Q1 Sales Remain Flat
While Roche continues to view China as a strategic growth market, a sharp 23% decline in Chinese diagnostics sales offset gains in other regions and segments. Despite near-term headwinds, Roche is betting on strong instrument placement growth across its Core Lab, Molecular, and Near Patient Care segments to fuel future demand for consumables and services–key components of its long-term medtech strategy.
Medtech Insight - April 29, 2025

Roche’s $50Bn Bet On US Manufacturing: Tariff Shield But Cash Flow Strain
New continuous glucose monitoring manufacturing site in Indiana is part of Roche’s plan to boost its US presence. Roche’s launch of Accu-Chek SmartGuide system last year with AI-powered prediction capabilities puts it as a key differentiator from competitors such as Abbott and Dexcom.
Medtech Insight - April 29, 2025

Medtech Seeks Inclusion In EU’s Groundbreaking Life Sciences Strategy
As the EU Life Sciences Strategy aims to drive innovation, the medtech sector is pushing for a pivotal role in a mission intended to embrace green and digital transitions, address regulatory obstacles and reduce dependency on external sources.
Medtech Insight - April 29, 2025

Exact Sciences Enters MRD Market With Oncodetect Launch But Faces Competition, Reimbursement Challenges
The Oncodetect test is tumor-informed, tracking up to 200 circulating tumor DNA (ctDNA) variants. It delivers simple “detected” or “not detected” results alongside quantitative data to guide adjuvant therapy decisions, monitor treatment response, and detects up to 200 ctDNA variants identifying signs of colorectal cancer recurrence up to two years earlier than imaging.
Medtech Insight - April 29, 2025

Cosmetics Consortium Shares Studies With FDA To Build Confidence In Animal Testing Alternatives
By guiding regulators through case studies and mock dossier examples of how to utilize new approach methodologies, the International Collaboration on Cosmetics Safety hopes to counter hesitations in replacing animal tests.
HBW Insight - April 30, 2025

Iconovo Slims Down As It Focuses On Commercialization
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.
Generics Bulletin - April 29, 2025

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’
Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.
Generics Bulletin - April 29, 2025

Glenmark’s UK Dapagliflozin Blocked On Appeal After Teva Readied Launch
Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.
Generics Bulletin - April 29, 2025

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
In Vivo - April 23, 2025

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
In Vivo - April 23, 2025

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.
In Vivo - April 23, 2025

Oncology’s Most Eligible Unpartnered Assets
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
In Vivo - April 23, 2025